The first‐dose pharmacokinetics of midazolam and its primary α‐hydroxy metabolite were
studied after single‐dose administration. Eligible study patients were enrolled into one of …

A serum concentration profile study on midazolam in children was done. Fifty six children
aged 3–10 years took part. The routes investigated were intravenous, intramuscular, rectal …

Twelve children 1-5 y old were randomly assigned to receive midazolam 0.2 mg. kg-1 either
by the intravenous (IV) or intranasal (IN) routes. After IN administration the rapid onset of …

Midazolam is a parenteral benzodiazepine with sedative, amnesic, anxiolytic, muscle
relaxant and anticonvulsant properties. The drug exerts its clinical effect by binding to a …

In France, the legal routes used to administer midazolam to a patient are intravenously and
intramuscularly. For anaesthetists, these routes are not well adapted to paediatric use; they …

Objective To describe the pharmacokinetics of midazolam, a water‐soluble benzodiazepine
with a short half‐life, in critically ill neonates. Hypothesis Midazolam clearance is reduced in …

The aim of the study was to study a possible pharmacokinetic-pharmacodynamic (PK-PD)
relationship for midazolam in pediatric intensive care patients and to determine how …

Midazolam is a benzodiazepine with rapid onset of action and short duration of effect. In
healthy neonates the half‐life (t1/2) and the clearance (Cl) are 3.3‐fold longer and 3.7‐fold …

Midazolam is a water soluble benzodiazepine, with a short elimination half-life in adults and
children. An IV bolus of midazolam 0.2 mg· kg− 1 was administered to 10 critically ill …

The pharmacokinetics of midazolam and 1-hydroxymethylmidazolam were investigated
following oral administration of 7.5, 15 and 30 mg doses of midazolam in solution to 12 …